Apellis Pharmaceuticals Inc
222 articles about Apellis Pharmaceuticals Inc
-
Apellis Reiterates Plans to Submit a New Drug Application in the First Half of 2022 for Pegcetacoplan for Geographic Atrophy Following FDA Feedback
11/12/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that it received formal, written feedback from the U.S. Food and Drug Administration (FDA) that further reinforces the company’s plans to submit a New Drug Application (NDA) for intravitreal pegcetacoplan for geographic atrophy (GA) secondary to age-related macular degeneration.
-
Apellis Announces Three Oral Presentations of the Phase 3 DERBY and OAKS Data in Geographic Atrophy (GA) to be Highlighted at the AAO Annual Meeting
11/10/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that data from the Phase 3 DERBY and OAKS studies will be presented as part of three oral presentations at the American Academy of Ophthalmology Annual Meeting to be held November 12 – 15, 2021 in New Orleans, Louisiana.
-
Apellis Pharmaceuticals Reports Third Quarter 2021 Financial Results
11/8/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced its third quarter 2021 financial results and business highlights.
-
Apellis to Present New Data Reinforcing EMPAVELI™ (pegcetacoplan) Efficacy and Safety in Patients with PNH at the 2021 ASH Annual Meeting
11/4/2021
Apellis Pharmaceuticals, Inc today announced that five abstracts were accepted for presentation at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021.
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 03, 2021
11/3/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the following investor conferences in November.
-
Apellis Pharmaceuticals to Host Conference Call on November 8, 2021 to Discuss Third Quarter 2021 Financial Results
11/1/2021
Apellis Pharmaceuticals today announced that the company will host a conference call and webcast to discuss its third quarter 2021 financial results on Monday, November 8, 2021 at 4:30 p.m. ET.
-
Apellis and Sobi Receive Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of PNH
10/15/2021
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of Aspaveli® for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are anemic after treatment with a C5 inhibitor for at least three months.
-
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 06, 2021
10/6/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to three new employees with a grant date of October 1, 2021, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
It was a busy week for clinical trial news. Here’s a look.
-
Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studies Presented at Retina Society Annual Meeting
9/30/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that detailed data from the Phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.
-
Apellis Pharmaceuticals to Present at the 2021 Cantor Virtual Global Healthcare Conference
9/20/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET.
-
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
-
Apellis Announces Top-Line Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022
9/9/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today reported top-line results from the Phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 07, 2021
9/7/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to one new employee with a grant date of September 1, 2021, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to New VP, Corporate Controller / Chief Accounting Officer
9/3/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller / Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021,
-
Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results
8/9/2021
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2021 financial results and business highlights.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 06, 2021
8/6/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company approved the grant of equity awards to three new employees with a grant date of August 2, 2021, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Host Conference Call on August 9, 2021 to Discuss Second Quarter 2021 Financial Results
7/29/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will host a conference call and webcast to discuss its second quarter 2021 financial results on Monday, August 9, 2021 at 4:30 p.m. ET.
-
Apellis Announces Closing of Previously Announced Exchanges of Approximately $201.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
7/26/2021
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced the closing of its previously announced privately negotiated exchange transactions with certain holders of its 3.500% Convertible Senior Notes due 2026.